Clearside Biomedical, Inc. CLSD · Stock Open Clearside Biomedical, Inc. in new tab
Clearside Biomedical, Inc. Analysis (CLSD)
Is Clearside Biomedical, Inc. a good investment? Clearside Biomedical, Inc. (CLSD) is currently trading at 0.4100 USD. Market analysts have a consensus price target of 60.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Clearside Biomedical, Inc. is expected to release its next earnings report on May 12, 2026. The market consensus estimate for Forward EPS is -0.50.
Investor FAQ
Does Clearside Biomedical, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Clearside Biomedical, Inc.?
Clearside Biomedical, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be May 12, 2026. The company currently has a trailing EPS of -5.11.
Company Profile
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 15, 2025 | 0.07 |
Community Discussion